From January 2018 to December 2020, a total of 222 consecutive patients diagnosed with HER2-low BC were screened, all of whom met eligibility criteria: 105 (47%) were classified with IHC1+ and 117 (53%) with IHC2+/ISH-. The gene discussed is ERBB2; the disease is breast cancer.